Topics:
Gynecologic Cancers • Ovarian Cancer
For an optimally cytoreduced, stage III ovarian carcinosarcoma, would you offer bevacizumab maintenance after completion of adjuvant carboplatin/taxol?
Patient is currently cycle 5/6 of carboplatin/taxol and tolerating well, has received no bevacizumab.
Answer from: at Community Practice
For an optimally cytoreduced patient with Stage III ovarian carcinosarcoma, I would not add bevacizumab unless the patient was "optimal" at interval surgery and had neoadjuvant and adjuvant use of bevacizumab with chemo and then to be continued in maintenance. The use of bevacizumab with chemo in th...
Sign in or Register to read more